Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis

Table 4 Associations between the six SNPs and response outcomes at 6 months

SNPs	Genotype (n)	DAS28 improvement			DAS28-LDA			CDAI improvement			CDAI-LDA
		Mean absolute value	Genetic model	p	%	Genetic model	p	Mean absolute value	Genetic model	p	%	Genetic model	p
rs4845625	T/T (9)	2.79	Cod	0.55	71.4	Cod	0.09	13.36	Cod	0.13	71.4	Cod	0.06
	C/T (28)	2.82	Rec	0.28	82.6	Rec	0.037	17.69	Rec	0.06	78.3	Rec	0.02
	C/C (25)	2.34			52.4			10.69			45.5
rs11265618	C/C (42)	2.91	Cod	0.08	73.5	Cod	0.12	15.64	Cod	0.31	73.5	Cod	0.08
	C/T (17)	1.87	Dom	0.048	50	Dom	0.29	10.12	Dom	0.18	40	Dom	0.039
	T/T (3)	2.82			100			15.66			66.7
rs4329505	T/T (42)	2.91	Cod	0.08	73.5	Cod	0.12	15.64	Cod	0.31	73.5	Cod	0.08
	C/T (17)	1.87	Dom	0.048	50	Dom	0.29	10.12	Dom	0.18	40	Dom	0.039
	C/C (3)	2.82			100			15.66			66.7
rs12083537	A/A (40)	2.36	Cod	0.21	72.7	Cod	0.26	13.37	Cod	0.48	63.6	Cod	0.35
	A/G (20)	3.13	Dom	0.10	64.7	Dom	0.39	16.05	Dom	0.56	66.7	Dom	0.97
	G/G (2)	2.05			0			3			0
rs2228145	A/A (22)	2.36	Cod	0.62	73.7	Cod	0.82	13.39	Cod	0.95	63.2	Cod	0.99
	C/A (27)	2.71	Dom	0.35	66.7	Dom	0.55	14.49	Dom	0.75	63.6	Dom	0.97
	C/C (13)	2.87			63.6			14.41			63.6
rs4537545	C/C (20)	2.31	Cod	0.50	72.7	Cod	0.92	13.27	Cod	0.91	61.1	Cod	0.95
	C/T (28)	2.68	Dom	0.29	66.7	Dom	0.68	14.06	Dom	0.73	63.6	Dom	0.79
	T/T (14)	2.96			66.7			15.23			66.7

Abbreviations: CDAI Clinical Disease Activity Index, Cod Codominant, DAS28 Disease Activity Score including 28 joints, Dom Dominant, p p-value, Rec Recessive, SNPs Single Nucleotide Polymorphisms

ISSN: 1478-6362